pentobarbital will reduce the level or result of isradipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.
pentobarbital will lessen the extent or effect of alosetron by affecting hepatic enzyme CYP2C9/10 metabolism. Slight/Significance Unidentified.
Contraindicated (one)pentobarbital decreases amounts of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Robust CYP3A4 inducers can cut down panobinostat ranges by ~70% and result in cure failure.
Warning is warranted for individuals with renal and hepatic impairment. While the company isn't going to provide unique dosage adjustment suggestions for renal impairment, checking kidney operate when administering high doses or conducting extended therapy is crucial.
pentobarbital will minimize the extent or effect of celecoxib by affecting hepatic enzyme CYP2C9/ten metabolism. Slight/Importance Mysterious.
pentobarbital increases toxicity of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. CYP3A4 inducers might improve the metabolism of ifosfamide to its Lively alkylating metabolites.
pentobarbital will reduce the level or effect of cariprazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the level or outcome of etonogestrel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will lessen the extent or impact of sildenafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Strong CYP3A4 inducers are expected to lead to considerable decreases in sildenafil plasma concentrations
pentobarbital will lower the extent or impact check here of duvelisib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with a powerful CYP3A inducer decreases duvelisib place under the curve (AUC), which can cut down duvelisib efficacy.
pentobarbital will lower the extent or influence of bedaquiline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Avoid coadministration of bedaquiline with robust CYP3A4 inducers due to likely for lessened therapeutic effect
pentobarbital will increase toxicity of methoxyflurane by rising metabolism. Contraindicated. Greater metabolism of methoxyflurane to nephrotoxic compounds.
Phenytoin and barbiturate blood amounts ought to be monitored extra commonly if specified concurrently; effect of barbiturates on phenytoin metabolism claimed to become variable; sodium valproate and valproic acid seem to lower barbiturate metabolism; check barbiturate blood concentrations and make correct dosage changes as required
pentobarbital will minimize the extent or result of dasatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.